Pathological definition of triple negative breast cancer

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 5-10

  Viale, Giuseppe ^a   Bottiglieri, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CYCLIN D1; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; P CADHERIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN S 100; SMOOTH MUSCLE ACTIN; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR; VIMENTIN;

ADENOID CYSTIC CARCINOMA; AGE DISTRIBUTION; APOCRINE CARCINOMA; ARTICLE; BASAL LIKE BREAST CARCINOMA; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST FIBROSIS; BREAST METASTASIS; BREAST NECROSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; DISEASE COURSE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; MEDULLARY CARCINOMA; MITOSIS; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 70349086914     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70011-5     Document Type: Article

References (22)

1. Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 (2006) 2137-2150
2. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 8 (2007) 235-244
3. Reis-Filho J.S., and Tutt A.N. Triple negative tumours: a critical review. Histopathology 52 (2008) 108-118
4. Carey L., Dees E.C., Sawyer L., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007) 2329-2334
5. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
6. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13 (2007) 4429-4434
7. Kreike B., van Kouwenhove M., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9 (2007) R65
8. Bidard F.C., Conforti R., Boulet T., Michiels S., Delaloge S., and André F. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 "triple-negative" breast cancers. Ann Oncol 18 (2007) 1285-1286
9. Mersin H., Yildirim E., Berberoglu U., and Gulben K. The prognostic importance of triple negative breast carcinoma. Breast 17 (2008) 341-346
10. Atchley D.P., Albarracin C.T., Lopez A., et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26 (2008) 4282-4288
11. Diaz L.K., Cryns V.L., Symmans F., and Sneige N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14 (2007) 419-430
12. Van den Eynden G.G., Colpaert C.G., Couvelard A., et al. A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation. Histopathology 51 (2007) 440-451
13. Lerma E., Peiro G., Ramon T., et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and HER2/neu (basal-like breast carcinomas). Mod Pathol 20 (2007) 1200-1207
14. Leibl S., Gogg-Kammerer M., Sommersacher A., Denk H., and Moinfar F. Metaplastic breast carcinomas: are they of myoepithelial differentiation? Immunohistochemical profilke of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 29 (2005) 347-353
15. Rakha E.A., Tan D.S., Foulkes W.D., et al. Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res 9 (2007) 404
16. Bertucci F., Finetti P., Cervera N., et al. How basal are triple-negative breast cancers?. Int J Cancer 123 (2008) 236-240
17. Weigelt B., Horlings H.M., Kreike B., et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216 (2008) 141-150
18. Ibrahim M., Dodson A., Barnett S., Fish D., Jasani B., and Miller K. Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am J Clin Pathol 129 (2008) 398-409
19. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human Epidermal Growth Factor Receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
20. Rakka E.A., El-Sayed M.E., Green A.R., Lee A., Robertson J.F., and Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 109 (2007) 25-32
21. Moinfair F. Is "basal-like" carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary note. Pathobiology 75 (2008) 119-131
22. Viale G., Rotmensz N., Maisonneuve P., et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116 (2009) 317-328